Commentary : Sustained reduction in disability progression in patients with primary progressive multiple sclerosis - follow-up study ORATORIO

Abstract

Commentary on a lecture given by Jerry S. Wolinsky at the Congress of Europeam Committee Treatment and Research in Multiple Sclerosis Stockholm (11.-13.

September 2019) on his research into the use of okrelizumab in the treatment of multiple sclerosis.

Keywords

• reduction of disability progression
• multiple sclerosis
• study ORATORIO
• okrelizumab